Literature DB >> 8297721

Mechanism of differential sensitivity of human bladder cancer cells to mitomycin C and its analogue.

B H Xu1, V Gupta, S V Singh.   

Abstract

This study was undertaken to elucidate the mechanism(s) of differential sensitivity of human bladder cancer cell lines J82 and SCaBER to mitomycin C (MMC) and its analogue, BMY 25067. The IC50 values for MMC and BMY 25067 in the SCaBER cell line were respectively 5- and 4-fold higher than in J82. BMY 25282 and BMY 25067 were significantly more cytotoxic, on a molar basis, than MMC in both the cell lines. NADPH cytochrome P450 reductase and DT diaphorase activities were significantly higher in the J82 cell line than in SCaBER, suggesting that relatively lower sensitivity of the SCaBER cell line to MMC and BMY 25067 may be due to deficient drug activation. This conclusion was supported by the observation that IC50 values for BMY 25282, which has lower quinone reduction potential than MMC and BMY 25067, did not differ significantly in these cell lines. A correlation between drug sensitivity, oxyradical formation and levels of antioxidative enzymes was not observed. These results suggest that the relatively lower sensitivity of SCaBER cells to MMC or BMY 25067 may be independent of differential oxyradical formation. MMC-induced DNA interstrand cross-link (ISC) formation was markedly lower in the SCaBER cell line than in J82. However, it remains to be seen if the reduced ISC frequency in the SCaBER cell line is a consequence of deficient drug activation or results from increased repair of the damaged DNA.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8297721      PMCID: PMC1968684          DOI: 10.1038/bjc.1994.46

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  29 in total

1.  DNA interstrand cross-link and free radical formation in a human multidrug-resistant cell line from mitomycin C and its analogues.

Authors:  L Dusre; S Rajagopalan; H M Eliot; J M Covey; B K Sinha
Journal:  Cancer Res       Date:  1990-02-01       Impact factor: 12.701

Review 2.  Mitomycin C in advanced breast cancer.

Authors:  L Lenaz
Journal:  Cancer Treat Rev       Date:  1985-12       Impact factor: 12.111

3.  Antitumor activity and toxicity in animals of N-7[2-(4-nitrophenyldithio) ethyl] mitomycin C (BMY-25067).

Authors:  W T Bradner; W C Rose; J E Schurig; A P Florczyk
Journal:  Invest New Drugs       Date:  1990       Impact factor: 3.850

4.  Generation of reactive oxygen radicals through bioactivation of mitomycin antibiotics.

Authors:  C A Pritsos; A C Sartorelli
Journal:  Cancer Res       Date:  1986-07       Impact factor: 12.701

Review 5.  Second generation analogs of etoposide and mitomycin C.

Authors:  T W Doyle; D M Vyas
Journal:  Cancer Treat Rev       Date:  1990-09       Impact factor: 12.111

6.  Isolation and structure of a covalent cross-link adduct between mitomycin C and DNA.

Authors:  M Tomasz; R Lipman; D Chowdary; J Pawlak; G L Verdine; K Nakanishi
Journal:  Science       Date:  1987-03-06       Impact factor: 47.728

7.  Potentiation of mitomycin C cytotoxicity by glutathione depletion in a multi-drug resistant mouse leukemia cell line.

Authors:  B H Xu; S V Singh
Journal:  Cancer Lett       Date:  1992-09-14       Impact factor: 8.679

8.  Isolation of Chinese hamster ovary cell mutants deficient in excision repair and mitomycin C bioactivation.

Authors:  A M Dulhanty; M Li; G F Whitmore
Journal:  Cancer Res       Date:  1989-01-01       Impact factor: 12.701

9.  Decreased NADPH:cytochrome P-450 reductase activity and impaired drug activation in a mammalian cell line resistant to mitomycin C under aerobic but not hypoxic conditions.

Authors:  P R Hoban; M I Walton; C N Robson; J Godden; I J Stratford; P Workman; A L Harris; I D Hickson
Journal:  Cancer Res       Date:  1990-08-01       Impact factor: 12.701

10.  Deficient activation by a human cell strain leads to mitomycin resistance under aerobic but not hypoxic conditions.

Authors:  R S Marshall; M C Paterson; A M Rauth
Journal:  Br J Cancer       Date:  1989-03       Impact factor: 7.640

View more
  6 in total

1.  Effect of selective inhibition of aquaporin 1 on chemotherapy sensitivity of J82 human bladder cancer cells.

Authors:  Xuefeng Zhang; Yun Chen; Liming Dong; Benkang Shi
Journal:  Oncol Lett       Date:  2018-01-04       Impact factor: 2.967

Review 2.  Emerging drug treatments for solid tumours.

Authors:  J H Schellens; L C Pronk; J Verweij
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

3.  Differential toxicity of mitomycin C and porfiromycin to aerobic and hypoxic Chinese hamster ovary cells overexpressing human NADPH:cytochrome c (P-450) reductase.

Authors:  M F Belcourt; W F Hodnick; S Rockwell; A C Sartorelli
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-09       Impact factor: 11.205

Review 4.  NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones.

Authors:  David Siegel; Chao Yan; David Ross
Journal:  Biochem Pharmacol       Date:  2011-12-24       Impact factor: 6.100

5.  Characterization of a BMS-181174-resistant human bladder cancer cell line.

Authors:  H Xia; R J Bleicher; X Hu; S K Srivastava; V Gupta; H A Zaren; S V Singh
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

6.  Chemical and biological characteristics of propolis from Apis mellifera caucasica from the Ardahan and Erzurum provinces of Turkey: a comparative study.

Authors:  Mehmet Arslan; Yusuf Sevgiler; Celal Güven; Zehra Tuğba Murathan; Nurcan Erbil; Deniz Yıldırım; Mehmet Büyükleyla; Şakire Karadaş; Rima Çelik; Eyyüp Rencüzoğulları
Journal:  Arh Hig Rada Toksikol       Date:  2021-03-30       Impact factor: 1.948

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.